Palvella Therapeutics (PVLA) Gross Margin (2014)

Palvella Therapeutics (PVLA) reported Gross Margin of 99.9% for Q3 2014.

Palvella Therapeutics (PVLA) Gross Margin (2014) Analysis & Trends

Palvella Therapeutics (PVLA) has 1 years of Gross Margin data on file, last reported at 99.9% in Q3 2014.

Gross Margin for Q3 2014 came in at 99.9%, changed N/A year-over-year; the trailing twelve-month figure through Sep 2014 was 2.6% (changed N/A YoY), and the FY2013 annual result was 100.0%, changed N/A from the prior year.
Gross Margin held at 99.9% in Q3 2014 per PVLA's latest filing.
Over five years, Gross Margin peaked at 99.9% in Q3 2014 and troughed at 99.9% in Q3 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	79.04%
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	86.85%
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Palvella Therapeutics	1.42 Bn	1.16 Bn	-	-

Historic Data

Download Data

Date	Value
Sep 30, 2014	99.90%